Posted in | News

NanoLogix Rapid Anthrax Detection Makes Progess

NanoLogix, Inc. is pleased to announce that major advances have been made in the rapid detection of Anthrax utilizing the NanoLogix BioNanoChannel Device.

here appears to be an opportunity to determine the viability and persistence of Anthrax spores much faster than current methods due to the unique rapid culturing aspects of the BNC technology. "Superb progress has been made in our research efforts simulating Anthrax spore growth through the use of non-hazardous spores. This research has the potential to immediately translate to the ability to conduct rapid Anthrax viability testing," said CEO Bret Barnhizer. "We have been impressed with the Department of Defense's dedication to finding the best solution for the security of our country in the event of a biological attack. We look forward to making a major contribution in this area by providing a method by which the government is able to determine the effectiveness of their decontamination efforts in hours rather than days."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoLogix. (2019, March 19). NanoLogix Rapid Anthrax Detection Makes Progess. AZoNano. Retrieved on December 13, 2024 from https://www.azonano.com/news.aspx?newsID=4826.

  • MLA

    NanoLogix. "NanoLogix Rapid Anthrax Detection Makes Progess". AZoNano. 13 December 2024. <https://www.azonano.com/news.aspx?newsID=4826>.

  • Chicago

    NanoLogix. "NanoLogix Rapid Anthrax Detection Makes Progess". AZoNano. https://www.azonano.com/news.aspx?newsID=4826. (accessed December 13, 2024).

  • Harvard

    NanoLogix. 2019. NanoLogix Rapid Anthrax Detection Makes Progess. AZoNano, viewed 13 December 2024, https://www.azonano.com/news.aspx?newsID=4826.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.